Cargando…
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
BACKGROUND: High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to tre...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236650/ https://www.ncbi.nlm.nih.gov/pubmed/25179671 http://dx.doi.org/10.1186/s12883-014-0169-0 |